Financial giants have made a conspicuous bearish move on SpringWorks Therapeutics. Our analysis of options history for SpringWorks Therapeutics SWTX revealed 9 unusual trades.
Delving into the details, we found 11% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $56,952, and 7 were calls, valued at $234,850.
Expected Price Movements
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $45.0 and $50.0 for SpringWorks Therapeutics, spanning the last three months.
Volume & Open Interest Trends
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for SpringWorks Therapeutics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of SpringWorks Therapeutics's whale trades within a strike price range from $45.0 to $50.0 in the last 30 days.
SpringWorks Therapeutics Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SWTX | CALL | TRADE | BULLISH | 06/20/25 | $10.0 | $8.9 | $10.0 | $50.00 | $50.0K | 1.4K | 0 |
| SWTX | CALL | TRADE | NEUTRAL | 04/17/25 | $8.7 | $8.3 | $8.5 | $50.00 | $42.5K | 3.3K | 412 |
| SWTX | CALL | TRADE | BEARISH | 04/17/25 | $8.7 | $8.5 | $8.5 | $50.00 | $33.1K | 3.3K | 452 |
| SWTX | CALL | TRADE | NEUTRAL | 03/21/25 | $4.0 | $2.6 | $3.3 | $50.00 | $33.0K | 2.9K | 155 |
| SWTX | PUT | TRADE | BEARISH | 04/17/25 | $6.0 | $5.7 | $6.0 | $45.00 | $30.0K | 391 | 50 |
About SpringWorks Therapeutics
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
After a thorough review of the options trading surrounding SpringWorks Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Current Position of SpringWorks Therapeutics
- With a trading volume of 402,511, the price of SWTX is down by -1.0%, reaching $49.34.
- Current RSI values indicate that the stock is is currently neutral between overbought and oversold.
- Next earnings report is scheduled for 44 days from now.
What The Experts Say On SpringWorks Therapeutics
In the last month, 2 experts released ratings on this stock with an average target price of $74.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * An analyst from HC Wainwright & Co. has revised its rating downward to Buy, adjusting the price target to $74. * An analyst from HC Wainwright & Co. has revised its rating downward to Buy, adjusting the price target to $74.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for SpringWorks Therapeutics, Benzinga Pro gives you real-time options trades alerts.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
